Aptevo Therapeutics Inc.
APVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | -74.7% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | -890.8% | -164.8% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 257.8% | -231.5% |
| EPS Diluted | -1,747.68 | -46,335 | 51,217 | -197,647 |
| % Growth | 96.2% | -190.5% | 125.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |